Alpha Thalassemia Pipeline Insight Pipeline Insight
DelveInsight’s, “Alpha Thalassemia – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Alpha Thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Alpha Thalassemia Understanding
Alpha Thalassemia: Overview
Alpha thalassemia is an inherited blood disorder that results in the reduced production of haemoglobin. Haemoglobin is an essential protein that is involved in the transportation of oxygen throughout the body. Alpha thalassemia is caused due to mutations in genes responsible for the productin of alpha globin. Depending on the number of alpha globin genes affected, it can result in four types of alpha thalassemia-silent alpha thalassemia, alpha thalassemia minor, haemoglobin H disease, and alpha thalassemia major or hydrops detalis.
"Alpha Thalassemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha Thalassemia pipeline landscape is provided which includes the disease overview and Alpha Thalassemia treatment guidelines. The assessment part of the report embraces, in depth Alpha Thalassemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha Thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Alpha Thalassemia R&D. The therapies under development are focused on novel approaches to treat/improve Alpha Thalassemia.
Alpha Thalassemia Emerging Drugs Chapters
This segment of the Alpha Thalassemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha Thalassemia Emerging Drugs
Agios Inc’s investigational drug candidate Mitaoivat is an activator of mutated as well as normal pyruvate kinase-R (PKR) enzymes. The drug is primarily being studied for PK deficiency but the company has expanded their research and clinical application of mitapavit into thalassemia as well as sickle cell disease. The drug is currently in the Phase II trial for thalassemia. The U.S. Food and Drug Administration granted the Orphan Drug Status to mitapivat for the treatment of thalassemia.
Further product details are provided in the report……..
Alpha Thalassemia: Therapeutic Assessment
This segment of the report provides insights about the different Alpha Thalassemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alpha Thalassemia
There are approx. 4+ key companies which are developing the therapies for Alpha Thalassemia. The companies which have their Alpha Thalassemia drug candidates in the most advanced stage, i.e. phase II include, Agios, Inc.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alpha Thalassemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha Thalassemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha Thalassemia drugs.
Alpha Thalassemia Report Insights
- Alpha Thalassemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Alpha Thalassemia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alpha Thalassemia drugs?
- How many Alpha Thalassemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha Thalassemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha Thalassemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha Thalassemia and their status?
- What are the key designations that have been granted to the emerging drugs?